An elec­tion night bereft of an­swers quells bio­phar­ma's 'worst-case' fears — an­a­lysts

5 years ago
Pharma
FDA+

Covid-19 roundup: Ox­ford in­ves­ti­ga­tor sees 's­mall chance' for vac­cine roll­out by year end; Fo­s­un fol­lows Pfiz­er with ...

5 years ago
Coronavirus

The End­points poll: A large ma­jor­i­ty of bio­phar­ma ex­ecs turn thumbs down on Bio­gen's con­tro­ver­sial pitch for ...

5 years ago
FDA+

With sales ris­ing and ef­fi­ca­cy ques­tions swirling, Gilead faces calls to re­lin­quish lu­cra­tive pri­or­i­ty re­view ...

5 years ago
R&D
FDA+

JW Ther­a­peu­tics hauls in $300M IPO just as liso-cel-in­spired CAR-T nears the fin­ish line in Chi­na

5 years ago
Financing
China

Promis­ing mR­NA tech comes with reg­u­la­to­ry, CMC headaches

5 years ago
Cell/Gene Tx
FDA+

News brief­ing: Gilead sub­mits fil­go­tinib to Eu­ro­pean reg­u­la­tors for UC; GW Phar­ma­ceu­ti­cals launch­es PhI­II tri­al for ...

5 years ago
News Briefing

An ‘in­no­cent by­stander’ in the boom­ing biotech in­vestor world is writ­ing a blank check for $100M. Who’s go­ing ...

5 years ago
Financing

Pre­vail and Alec­tor both claim vic­to­ry in ar­bi­tra­tion over sci­en­tist-CEO, telling di­ver­gent tales of con­fi­den­tial ...

5 years ago
People
Pharma

Small cap im­munother­a­py play­er Zio­pharm faces an ac­tivist at­tack, re­bukes call for board seats

5 years ago
Pharma

PS: Did any­one at Bio­gen ask the FDA to pull an ad­u­canum­ab con­sci­en­tious ob­jec­tor off their ex­pert pan­el? ‘No ...

5 years ago
R&D
FDA+

Jounce shares take a beat­ing as their lead drug spurs on­ly a weak re­sponse in PhII — tri­al halt­ed

5 years ago
R&D

The End­points News poll: Should the FDA pan­el back an ap­proval for ad­u­canum­ab, or should they send Bio­gen pack­ing?

5 years ago
FDA+

Covid-19 roundup: CEPI pours $328M in­to Clover's vac­cine; For­mer Shkre­li com­pa­ny li­cens­es po­ten­tial treat­ment for ...

5 years ago
Coronavirus

Eye­ing com­mer­cial­iza­tion, a Shang­hai-based CAR-T start­up nabs a $186M megaround

5 years ago
Deals
China

Bris­tol My­ers wins a big bet as their PhI­II au­toim­mune drug beat out block­buster Ote­zla — and that could cost Am­gen ...

5 years ago
R&D

Sana Biotech­nol­o­gy snags Os­cine, adding cell ther­a­py leader Steve Gold­man to its star-stud­ded staff

5 years ago
Deals
Cell/Gene Tx

Can a dark­horse syn­thet­ic bi­ol­o­gy Covid-19 vac­cine one-up the fron­tun­ners? The Gates Foun­da­tion, Am­gen bet 'yes'

5 years ago
R&D
Coronavirus

A lit­tle biotech's sec­ond crack at dry eye dis­ease comes up short. And this time there will be no ex­tra shot at ...

5 years ago
R&D

Covid-19 roundup: Russ­ian biotech seeks per­mis­sion to pro­duce remde­sivir gener­ic; Why did BAR­DA fund plas­ma com­pa­ny ...

5 years ago
Coronavirus

Or­chard halts dos­ing of EMA-ap­proved Strimvelis af­ter pa­tient de­vel­ops leukemia

5 years ago
FDA+

PerkinElmer buys out British gene edit­ing play­er for $383M, boost­ing its di­ag­nos­tics and ge­nom­ic ca­pa­bilites

5 years ago
Deals

News brief­ing: FDA lifts a hold on Po­sei­da study; Deci­bel adopts 2-AAV ap­proach to hear­ing loss; As­traZeneca part­ners ...

5 years ago
News Briefing

Roy­al­ty Phar­ma tops its record-set­ting $3.3B deal with CF Foun­da­tion, bet­ting $575M more on Ver­tex's drugs

5 years ago
Deals
First page Previous page 781782783784785786787 Next page Last page
A service from the Financial Times